Skip to content

Author

L. Tokgozoglu

We have 3 of 17 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Interleukin-6 predicts cardiovascular events beyond standard modifiable risk factors in individuals without atherosclerotic cardiovascular disease

Current risk stratification algorithms capture high-risk individuals with classical risk factors or established atherosclerotic cardiovascular disease (ASCVD). However, a clinically relevant proportion of individuals without threshold levels of standard modifiable risk factors (SMuRF) – namely hypertension, dysli...

F. Kahles, B. Kurt, K. Schneider et al. · 0 citations
Aug 2026

Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study.

The addition of evolocumab reduced the total number of MACE, providing support for the role of intensive low-density lipoprotein cholesterol lowering to prevent first and subsequent MACE in patients at high cardiovascular risk and no prior MI or stroke.

José C. Nicolau, S. Murphy, Robert P. Giugliano et al. · 1 citation
Review Open access Aug 2026

Lipoprotein(a) and Aortic Stenosis: From Genetic Risk to Emerging Therapeutic Strategies

Experimental and translational data suggest that lipoprotein(a) exerts its effects early in the disease course, promoting valve inflammation and calcification before significant stenosis develops, raising the possibility that early lipoprotein(a)-lowering may modify disease progression, a hypothesis now being tested in...

L. Tokgozoglu, M. Kayıkçıoğlu · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.